These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38871614)

  • 1. In vitro induction and selection of fluoroquinolone-resistant mutants in Elizabethkingia anophelis.
    Lee CC; Lai CH; Lin SY; Lee NY; Liu PY; Yang CH; Huang YH; Lin JN
    J Microbiol Immunol Infect; 2024 Jun; ():. PubMed ID: 38871614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic Combination to Effectively Postpone or Inhibit the In Vitro Induction and Selection of Levofloxacin-Resistant Mutants in
    Lee CC; Lai CH; Yang CH; Huang YH; Lin JN
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant Prevention Concentrations of Ciprofloxacin and Levofloxacin and Target Gene Mutations of Fluoroquinolones in Elizabethkingia anophelis.
    Lin IF; Lai CH; Lin SY; Lee CC; Lee NY; Liu PY; Yang CH; Huang YH; Lin JN
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0030122. PubMed ID: 35708332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular typing and profiling of topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in
    Jian MJ; Cheng YH; Perng CL; Shang HS
    PeerJ; 2018; 6():e5608. PubMed ID: 30225179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolone resistance in carbapenem-resistant Elizabethkingia anophelis: phenotypic and genotypic characteristics of clinical isolates with topoisomerase mutations and comparative genomic analysis.
    Jian MJ; Cheng YH; Chung HY; Cheng YH; Yang HY; Hsu CS; Perng CL; Shang HS
    J Antimicrob Chemother; 2019 Jun; 74(6):1503-1510. PubMed ID: 30830171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan.
    Lin JN; Lai CH; Yang CH; Huang YH
    J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30545016
    [No Abstract]   [Full Text] [Related]  

  • 8. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of fluoroquinolone resistance and mutations in the gyrA, parC and parE genes of Riemerella anatipestifer isolated from ducks in China.
    Zhu D; Zheng M; Xu J; Wang M; Jia R; Chen S; Liu M; Zhao X; Yang Q; Wu Y; Zhang S; Huang J; Liu Y; Zhang L; Yu Y; Pan L; Chen X; Cheng A
    BMC Microbiol; 2019 Dec; 19(1):271. PubMed ID: 31795952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
    Ling JM; Chan EW; Lam AW; Cheng AF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.
    Giraud E; Brisabois A; Martel JL; Chaslus-Dancla E
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2131-7. PubMed ID: 10471553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
    Nathania I; Nainggolan IM; Yasmon A; Nusatia ACM; Tjoa E; Gunardi WD; Moehario LH
    BMC Microbiol; 2022 Oct; 22(1):250. PubMed ID: 36253712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The determination of gyrA and parC mutations and the prevalence of plasmid-mediated quinolone resistance genes in carbapenem resistant Klebsiella pneumonia ST11 and ST76 strains isolated from patients in Heilongjiang Province, China.
    Zeng L; Zhang J; Li C; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Zhang X
    Infect Genet Evol; 2020 Aug; 82():104319. PubMed ID: 32278145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
    Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types.
    Billal DS; Fedorko DP; Yan SS; Hotomi M; Fujihara K; Nelson N; Yamanaka N
    J Antimicrob Chemother; 2007 Jan; 59(1):28-34. PubMed ID: 17065188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.